Timothy Voskuijl1, Michiel Hageman, David Ring. 1. Department of Orthopaedic Surgery, Massachusetts General Hospital, Yawkey Center, Suite 2100, 55 Fruit Street, Boston, MA, 02114, USA.
Abstract
BACKGROUND: The Charlson Comorbidity Index (CCI) originally was developed to predict mortality within 1 year of hospital admission in patients without trauma. As it includes factors associated with medical and surgical complexities, it also may be useful as a predictive tool for hospital readmission after orthopaedic surgery, but to our knowledge, this has not been studied. QUESTIONS/PURPOSES: We asked whether an increased score on the CCI was associated with (1) readmission, (2) an increased risk of surgical site infection or other adverse events, (3) transfusion risk, or (4) mortality after orthopaedic surgery. METHODS: A total of 30,129 orthopaedic surgeries performed between 2008 and 2011 without any orthopaedic surgery in the preceding 30 days were analyzed. International Classification of Diseases, 9(th) Revision codes were used to identify diagnoses, procedures, surgery-related adverse events, surgical site infection, and comorbidities as listed in the updated and reweighted CCI. A total of 913 patients (3.0%) were readmitted within 30 days after discharge; in 393 (1.4%) patients adverse events occurred; 417 patients (1.4%) had a surgical site infection develop; 211 (0.7%) needed transfusions, and 56 (0.2%) died within 30 days after surgery. Ordinary least squares regression analyses were used to determine whether the CCI was associated with these outcomes. RESULTS: The CCI accounted for 10% of the variation in readmissions. Every point increase in CCI score added an additional 0.45% risk in readmission for patients undergoing arthroplasty, 0.63% for patients undergoing trauma surgery, and 0.9% risk for patients undergoing spine surgery (all p < 0.01). The CCI was not associated with surgical site infection or other adverse events, but accounted for 8% of the variation in transfusion rate and 10% of the variation in mortality within 30 days of surgery. CONCLUSIONS: The CCI can be used to estimate the risk of readmission after arthroplasty, hand and upper extremity surgery, spine surgery, and trauma surgery. It also can be used to estimate the risk of transfusion after arthroplasty, spine, trauma, and oncologic orthopaedic surgery and the risk of mortality after shoulder, trauma, and oncologic orthopaedic surgery. LEVEL OF EVIDENCE: Level IV, prognostic study. See the Instructions for Authors for a complete description of levels of evidence.
BACKGROUND: The Charlson Comorbidity Index (CCI) originally was developed to predict mortality within 1 year of hospital admission in patients without trauma. As it includes factors associated with medical and surgical complexities, it also may be useful as a predictive tool for hospital readmission after orthopaedic surgery, but to our knowledge, this has not been studied. QUESTIONS/PURPOSES: We asked whether an increased score on the CCI was associated with (1) readmission, (2) an increased risk of surgical site infection or other adverse events, (3) transfusion risk, or (4) mortality after orthopaedic surgery. METHODS: A total of 30,129 orthopaedic surgeries performed between 2008 and 2011 without any orthopaedic surgery in the preceding 30 days were analyzed. International Classification of Diseases, 9(th) Revision codes were used to identify diagnoses, procedures, surgery-related adverse events, surgical site infection, and comorbidities as listed in the updated and reweighted CCI. A total of 913 patients (3.0%) were readmitted within 30 days after discharge; in 393 (1.4%) patients adverse events occurred; 417 patients (1.4%) had a surgical site infection develop; 211 (0.7%) needed transfusions, and 56 (0.2%) died within 30 days after surgery. Ordinary least squares regression analyses were used to determine whether the CCI was associated with these outcomes. RESULTS: The CCI accounted for 10% of the variation in readmissions. Every point increase in CCI score added an additional 0.45% risk in readmission for patients undergoing arthroplasty, 0.63% for patients undergoing trauma surgery, and 0.9% risk for patients undergoing spine surgery (all p < 0.01). The CCI was not associated with surgical site infection or other adverse events, but accounted for 8% of the variation in transfusion rate and 10% of the variation in mortality within 30 days of surgery. CONCLUSIONS: The CCI can be used to estimate the risk of readmission after arthroplasty, hand and upper extremity surgery, spine surgery, and trauma surgery. It also can be used to estimate the risk of transfusion after arthroplasty, spine, trauma, and oncologic orthopaedic surgery and the risk of mortality after shoulder, trauma, and oncologic orthopaedic surgery. LEVEL OF EVIDENCE: Level IV, prognostic study. See the Instructions for Authors for a complete description of levels of evidence.
Authors: Carlos A Higuera; Karim Elsharkawy; Alison K Klika; Matthew Brocone; Wael K Barsoum Journal: Clin Orthop Relat Res Date: 2011-02-23 Impact factor: 4.176
Authors: Ross A Schumer; Jonathan S Chae; Ronald J Markert; Dominic Sprott; Lynn A Crosby Journal: J Shoulder Elbow Surg Date: 2010-01 Impact factor: 3.019
Authors: Stavros G Memtsoudis; Yan Ma; Ya Lin Chiu; J Matthias Walz; Robert Voswinckel; Madhu Mazumdar Journal: Anesth Analg Date: 2010-09-14 Impact factor: 5.108
Authors: Carlos B Mantilla; C Thomas Wass; Karissa A Goodrich; Cassie J Johanns; Michelle L Kool; Xun Zhu; Jose A Corredor; David O Warner; Michael J Joyner; Daniel J Berry; Darrell R Schroeder; Juraj Sprung Journal: Transfusion Date: 2011-01 Impact factor: 3.157
Authors: Nelson F Soohoo; Eugene Farng; Jay R Lieberman; Lauchlan Chambers; David S Zingmond Journal: Clin Orthop Relat Res Date: 2010-09 Impact factor: 4.176
Authors: Chukwuweike U Gwam; Nicole E George; Jennifer I Etcheson; Samuel Rosas; Johannes F Plate; Ronald E Delanois Journal: J Knee Surg Date: 2018-11-05 Impact factor: 2.757
Authors: Daniel C Norvell; Jane B Shofer; Sigvard T Hansen; James Davitt; John G Anderson; Donald Bohay; J Chris Coetzee; John Maskill; Michael Brage; Michael Houghton; William R Ledoux; Bruce J Sangeorzan Journal: Foot Ankle Int Date: 2018-05-31 Impact factor: 2.827
Authors: Stein J Janssen; Andrea S van der Heijden; Maarten van Dijke; John E Ready; Kevin A Raskin; Marco L Ferrone; Francis J Hornicek; Joseph H Schwab Journal: Clin Orthop Relat Res Date: 2015-07-09 Impact factor: 4.176
Authors: Elizabeth W Paxton; Maria C S Inacio; Jasvinder A Singh; Rebecca Love; Stefano A Bini; Robert S Namba Journal: Clin Orthop Relat Res Date: 2015-11 Impact factor: 4.176
Authors: Douglas S Weinberg; Matthew J Kraay; Steven J Fitzgerald; Vasu Sidagam; Glenn D Wera Journal: Clin Orthop Relat Res Date: 2016-11-11 Impact factor: 4.176
Authors: Stein J Janssen; Yvonne Braun; John E Ready; Kevin A Raskin; Marco L Ferrone; Francis J Hornicek; Joseph H Schwab Journal: Clin Orthop Relat Res Date: 2015-01-31 Impact factor: 4.176
Authors: Sara L Zettervall; Jeremy L Holzmacher; Michal Radomski; Matthew Skancke; Justin Shafa; Richard Amdur; Babak Sarani; Khashayar Vaziri Journal: J Gastrointest Surg Date: 2017-06-28 Impact factor: 3.452